switching from zepbound to compounded tirzepatide Injections $100 CAUTION: Switching From Zepbound To

Schedule your consult today and experience what it's like to feel seen, supported, and successful on your path to wellness

Combined with Usnea Barbata and Pulsatilla Koreana, these three extracts are claimed to form a natural preservative system that also has anti-inflammatory effects and might help with skin conditions such as blemishes, atopic dermatitis, and dandruff

in the Journal of Medicinal Chemistry

NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage